On December 2, 2020 Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) ("Pascal" or the "Company") and SōRSE Technology Corporation ("SōRSE") reported that have validated and optimized a formula for oral cannabinoid delivery (Press release, Pascal Biosciences, DEC 2, 2020, View Source [SID1234572398]). Their shared efforts are advancing the cannabinoid PAS-393 towards clinical testing against cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This progress is very promising because this step is critical for testing in human volunteers," said Patrick Gray, CEO. "We will next identify a drug product manufacturer to prepare our product for testing in cancer patients treated with checkpoint inhibitors."

This will be the first pharmaceutical use of the novel formulation technology developed by SōRSE and the first clinical trial for Pascal and SōRSE. The collaboration utilizes propriety discoveries by both companies, including Pascal’s intellectual property, which covers the use of cannabinoids in cancer patients treated with checkpoint inhibitors, and SōRSE’s proprietary formulation expertise.

"It’s great to see such rapid progress with the invitro studies using our formulation technology," said SōRSE CEO Howard Lee. "We are on track to enter our first clinical trial with Pascal within a year."

Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SōRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor.